News
ADXS
0.027
NaN%
--
Weekly Report: what happened at ADXS last week (1021-1025)?
Weekly Report · 4d ago
Weekly Report: what happened at ADXS last week (1014-1018)?
Weekly Report · 10/21 10:45
Weekly Report: what happened at ADXS last week (1007-1011)?
Weekly Report · 10/14 11:07
Weekly Report: what happened at ADXS last week (0930-1004)?
Weekly Report · 10/07 10:58
Weekly Report: what happened at ADXS last week (0923-0927)?
Weekly Report · 09/30 10:53
Weekly Report: what happened at ADXS last week (0916-0920)?
Weekly Report · 09/23 10:52
Weekly Report: what happened at ADXS last week (0909-0913)?
Weekly Report · 09/16 10:44
Weekly Report: what happened at ADXS last week (0902-0906)?
Weekly Report · 09/09 10:53
Weekly Report: what happened at ADXS last week (0826-0830)?
Weekly Report · 09/02 10:56
Weekly Report: what happened at ADXS last week (0819-0823)?
Weekly Report · 08/26 10:54
Weekly Report: what happened at ADXS last week (0812-0816)?
Weekly Report · 08/19 10:43
Weekly Report: what happened at ADXS last week (0805-0809)?
Weekly Report · 08/12 10:45
Weekly Report: what happened at ADXS last week (0729-0802)?
Weekly Report · 08/05 10:54
Weekly Report: what happened at ADXS last week (0722-0726)?
Weekly Report · 07/29 10:46
Weekly Report: what happened at ADXS last week (0715-0719)?
Weekly Report · 07/22 10:46
Weekly Report: what happened at ADXS last week (0708-0712)?
Weekly Report · 07/15 10:44
Weekly Report: what happened at ADXS last week (0701-0705)?
Weekly Report · 07/08 10:45
Weekly Report: what happened at ADXS last week (0624-0628)?
Weekly Report · 07/01 10:45
Immunome: AL102 And Other Established Protein Targets Could Drive Value
Seeking Alpha · 06/27 18:14
Weekly Report: what happened at ADXS last week (0617-0621)?
Weekly Report · 06/24 10:51
More
Webull provides a variety of real-time ADXS stock news. You can receive the latest news about Ayala Pharm through multiple platforms. This information may help you make smarter investment decisions.
About ADXS
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company primarily focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. The Company's lead candidate is aspacytarabine (BST-236), a novel anti-metabolite for first line treatment in unfit acute myeloid leukemia (AML). Aspacytarabine (BST-236) is composed of cytarabine covalently bound to asparagine, acting as a pro-drug of cytarabine. It is also focused on the development and commercialization of proprietary Listeria monocytogenes (Lm)-based antigen delivery products. These efforts are primarily focused on the development of ADXS-504, a Lm-based therapy for early-stage prostate cancer.